Protocol: ADA Bridging ELISA for Use with Anti-Nirsevimab (Beyfortus) Antibodies

Protocol: ADA Bridging ELISA for Use with Anti-Nirsevimab (Beyfortus) Antibodies

Protocol: ADA Bridging ELISA for Use with Anti-Nirsevimab (Beyfortus) Antibodies

Protocol: ADA Bridging ELISA for Use with Anti-Nirsevimab (Beyfortus) Antibodies

Download PDF 

Anti-Drug Antibody (ADA) Bridging ELISA: For Use with Anti-Nirsevimab Monoclonal Antibodies Catalog HCA450, HCA451, HCA452

This method provides a procedure for generating an ADA ELISA standard curve with Anti-Nirsevimab Antibody, HCA450, HCA451, HCA452, using nirsevimab antibody for capture and detection. The method should always be used in conjunction with product and batch-specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.


Reagents

BSA (Sigma-Aldrich, A7906)
HISPEC Assay Diluent  (BUF049)
Human Serum (Sigma-Aldrich, H4522)
Phosphate buffered saline (PBS)
136 mM NaCl
2.68 mM KCl
8.1 mM Na2HPO4
1.46 mM KH2PO4
PBST
PBS with 0.05% Tween 20 (Merck Millipore, 817072)
QuantaBlu Fluorogenic Peroxidase Substrate (Thermo Fisher Scientific, 15169)
LYNX Rapid Plus Biotin (Type 2) Antibody Conjugation Kit™ (e.g., LNK273B) or LYNX Rapid Plus Biotin (Type 1) Antibody Conjugation Kit (e.g., LNK263B)
Pierce High Sensitivity NeutrAvidin-HRP (Thermo Scientific, 31030)

Materials

384-well microtiter plate, black, square flat-bottom wells, for example, Black 384-Well Immuno Plates (Thermo Fisher Scientific, 460518)
Fluorescence plate reader
96-well plates can be used instead of 384-well plates (black, flat-bottom wells), for example, Black 96-Well Immuno Plates (Thermo Fisher Scientific, 437111). For the 96-well format, use 100 μL (instead of 20 μL) of antigen, antibodies, or substrate and 300 μL for the blocking step.

Method

  1. Prepare detection antibody: conjugate nirsevimab antibody using a LYNX Rapid Plus Biotin Antibody Conjugation Kit.
  2. Prepare the unconjugated nirsevimab capture antibody at 1 µg/mL in PBS. Coat the required number of wells of a 384-well microtiter plate with 20 µL per well of the prepared nirsevimab, and incubate overnight at 4°C.
  3. Wash the microtiter plate five times (5x) with PBST.
  4. Block the microtiter plate by adding 100 µL 5% BSA in PBST to each well, and then incubate for 1 hr at RT.
  5. Wash the microtiter plate 5x with PBST.
  6. For the standard curve, prepare a dilution series of the Anti-Nirsevimab Antibody, HCA450, HCA451, HCA452, in 10% human serum in PBST in triplicate. Final concentration of anti-nirsevimab antibody should cover the range from 0.008 ng/mL to 32,000 ng/mL. Include a zero anti-nirsevimab antibody concentration as the background value.
  7. Add 20 µL of anti-nirsevimab antibody dilution per well (in triplicate for each standard recommended) and incubate for 1 hr at RT.
  8. Wash the microtiter plate 5x with PBST.
  9. To each well add 20 µL biotinylated nirsevimab diluted to 2 µg/mL in HISPEC Assay Diluent and incubate for 1 hr at RT.
  10. Wash the microtiter plate 5x with PBST.
  11. To each well add 20 µL NeutrAvidin-HRP diluted to 0.125 µg/mL (1:8,000) in HISPEC Assay Diluent and incubate for 1 hr at RT.
  12. Wash the microtiter plate 10x with PBST.
  13. Add 20 µL QuantaBlu Fluorogenic Peroxidase Substrate to each well and measure the fluorescence after 30 min.